Research·October 25, 2026 at 6:00 AM EDT·1 source
#ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity
PFE -1.3%BNTXBMY
PFE · last 30 trading days-1.3% since the news
News
What happened
- Pfizer is moving beyond a late-stage loss in non-small cell lung cancer.
- A post-hoc analysis suggested earlier-line patients may benefit from Pfizer’s treatment.
- BioNTech and Bristol Myers Squibb reported early activity at ESMO26.
Why it matters
The update may influence how healthcare professionals assess clinical-development prospects in lung cancer and the broader oncology pipeline.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- EarlierOct 13BioNTech’s head and neck cancer vaccine misses first of two goals
- EarlierOct 13Beam suggests it can correct mutation; Pfizer to collaborate with Enodia
- EarlierOct 22Pfizer details mixed Lyme disease vaccine data
- EarlierOct 23Bristol Myers reveals autoimmune CAR-T trial death, explains summertime pause
- First reported by Endpoints News10h#ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity
Who is involved
#ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Br…PfizerPFEBioNTechBNTXBristol Myers SquibbBMY
Company
Sources (1)
Related
- 5h · #ESMO26: Roche details magnitude of its KRAS G12C inhibitor’s win over rivals in lung cancer trial
- 5h · Roche Drug Outshines Amgen, Bristol Rivals in Lung Cancer Study
- Oct 23 · Bristol Myers reveals autoimmune CAR-T trial death, explains summertime pause
- Oct 22 · Pfizer details mixed Lyme disease vaccine data
- Oct 13 · BioNTech’s head and neck cancer vaccine misses first of two goals
- Oct 13 · Beam suggests it can correct mutation; Pfizer to collaborate with Enodia
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.